Vincristine (Oncovin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Notable side effects

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 1995-04-12: EURD

History of changes in PMDA indication

  • 2013-03-25: New additional indication and a new dosage for the treatment of pheochromocytoma.

Also known as

  • Generic names: LCR, leurocristine, VCR, vincristine sulfate
  • Brand names:
Alcrist Biocrist Biocrystin Cellcristin Citomid Crivosin Farmistin CS Fauldvincri
Krebin Kyocristine Nevexitin Oncovin Onkocristin Pericristine Pharmacristine Tecnocris
Vincasar Vinces Vincosid Vincran Vincrex Vincrifil Vincrin Vincrisin
Vincrisol Vincristin Vincristina Vincristinesulfaat Vincristinsulfat Vincristinum Vincrisul Vinracin
Vinracine Vinstin Vintec


  1. 1.0 1.1 Vincristine (Oncovin) package insert
  2. Vincristine (Oncovin) package insert (locally hosted backup)
  3. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article contains dosing details in manuscript PubMed
  4. Vincristine (Oncovin) patient drug information (Chemocare)
  5. Vincristine (Oncovin) patient drug information (UpToDate)